Pharma

Your Article Summary

See Latest Articles

Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Takeda Pharmaceuticals North America, 07/02/09

Takeda Pharmaceutical Company Limited announced that Takeda Global Research and Development Center, Inc., a wholly owned United States subsidiary received on June 26 a complete response letter from the U.S. Food and Drug Administration regarding the Company's New Drug Application for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09

Review calls for EHR action in Saskatchewan
Canadian Healthcare Technology, 11/20/09

New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
Chugai Pharmaceutical Co., 11/04/09

See All of Regulatory Issues